This Announcement contains inside information for the purposes of Regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310,
Ideagen PLC
("Ideagen," "the Company" or the "Group'')
Issue of Equity, PDMR Dealing and Total Voting Rights
Ideagen PLC (AIM: IDEA), a leading supplier of Information Management Software to highly regulated industries, announces that yesterday it allotted a total of 167,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Company.
In addition, Graeme Spenceley, Company Secretary and a PDMR of the Company, yesterday sold 200,000 Ordinary Shares at a price of 285 pence per Ordinary Share (the "Sale").
Application has been made to the London Stock Exchange for the 167,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 01 March 2021.
After Admission, the total number of Ordinary Shares in issue will be 252,292,074 and the total number of voting rights will therefore be 252,292,074. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
| Ideagen plc | 01629 699 100 |
| Ben Dorks, Chief Executive Officer | |
| Emma Hayes, Chief Financial Officer
| |
| | |
| finnCap Limited | 020 7220 0500 |
| Henrik Persson/James Thompson (Nomad) | |
| Alice Lane (ECM)
| |
| Canaccord Genuity | 020 7523 8000 |
| Simon Bridges | |
| Richard Andrews | |
About Ideagen plc
Ideagen is a UK-headquartered, global technology company quoted on the London Stock Exchange AIM market (Ticker: IDEA.L).
A global supplier of regulatory and compliance solutions, Ideagen provides a common software platform and an integrated risk-based approach to meet multi-industry standards, enabling compliance with relevant laws, policies, and regulations.
The Group provides software and services to organisations operating within highly regulated industries such as life sciences, healthcare, banking and finance, insurance, aviation, and aerospace and defence, with its main operational premises spread throughout the UK, EU, US, Middle East and SE Asia.
Currently, more than 5,700 organisations use Ideagen's products including eight of the top 10 UK accounting firms, all of the top aerospace and defence companies and 75% of the world's leading pharmaceutical firms.
Ideagen's diverse and varied customer base includes many well-known, global brands such as British Airways, Aggreko, BAE, Ryanair, US Navy, KLM, BBVA, Bank of New York, Commerzbank, Meggitt, Heineken, Johnson Matthey, Haeco Group and European Central Bank. As well as this, Ideagen counts 250 hospitals across the UK and US amongst its client base. For further information please visit www.ideagen.com .
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Graeme Spenceley | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Company Secretary | ||||
| b) | Initial notification/Amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | Ideagen plc | ||||
| b) | LEI | 213800KS1MLITOVNYC85 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument
| Ordinary Shares | ||||
| Identification code | GB00B0CM0C50 | |||||
| b) | Nature of the transaction | Sale of Ordinary Shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information: · Aggregated volume · Price |
n/a | ||||
| e) | Date of the transaction | 22 February 2021 | ||||
| f) | Place of the transaction | London Stock Exchange, AIM (XLON) | ||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
